Skip to main content
Top
Published in: Modern Rheumatology 6/2013

01-11-2013 | Rapid Communication

Upregulation of VEGF expression is associated with accumulation of HIF-1α in the skin of naïve scleroderma patients

Authors: Maria Ioannou, Athina Pyrpasopoulou, Georgios Simos, Efrosyni Paraskeva, Christina Nikolaidou, Ioannis Venizelos, Georgios Koukoulis, Spyros Aslanidis, Stella Douma

Published in: Modern Rheumatology | Issue 6/2013

Login to get access

Abstract

Systemic sclerosis is a disease hallmarked by microangiopathy; the enlargement and leakage of skin capillaries in active stages develops into extensive avascular areas, clinically associated with severe tissue hypoxia and the formation of digital ulcers. Vascular endothelial growth factor (VEGF) is upregulated in all stages of the disease, with little effect on efficient neovascularization. The oxygen-regulated α-subunit of hypoxia-inducible transcription factor-1 (HIF-1α) represents a key mechanism involved in the transcriptional regulation of VEGF. The aim of this study is to investigate expression of the oxygen-regulated α-subunit of HIF-1 and VEGF in naïve scleroderma patients. For this purpose, skin biopsies (dorsal hand surface) from scleroderma patients were analyzed and compared with control skin biopsies. Immunoreactivity for VEGF was enhanced in scleroderma patients, in contrast to restricted positive immunostaining in suprabasal keratinocytes observed in normal skin. In a similar fashion, all skin biopsies from scleroderma patients were strongly HIF-1α reactive, compared with rare immunoreactivity observed in normal skin. The pattern was similar in all stages of scleroderma. These observations for the first time directly connect constitutive hypoxia with VEGF upregulation in scleroderma patients. The sequence of events needs to be precisely mapped, and the pro- and antiangiogenic switches which may interfere with efficient tissue neovascularization identified, in order to provide meaningful therapeutic strategies.
Literature
1.
go back to reference Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med. 2010;14:1241–54.PubMedCrossRef Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med. 2010;14:1241–54.PubMedCrossRef
2.
go back to reference Beyer C, Schett G, Gay S, Distler O, Distler JH. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthr Res Ther. 2009;11:220.CrossRef Beyer C, Schett G, Gay S, Distler O, Distler JH. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthr Res Ther. 2009;11:220.CrossRef
3.
go back to reference Distler JH, Strapatsas T, Huscher D, Dees C, Akhmetshina A, Kiener HP, et al. Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Ann Rheum Dis. 2011;70:1197–202.PubMedCrossRef Distler JH, Strapatsas T, Huscher D, Dees C, Akhmetshina A, Kiener HP, et al. Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Ann Rheum Dis. 2011;70:1197–202.PubMedCrossRef
4.
go back to reference Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 2006;45 Suppl 3 iii:26–7. Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 2006;45 Suppl 3 iii:26–7.
5.
go back to reference Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–13.PubMed Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–13.PubMed
6.
go back to reference Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004;95:109–16.PubMedCrossRef Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004;95:109–16.PubMedCrossRef
7.
go back to reference Ioannou M, Mylonis I, Kouvaras E, Papamichali R, Daponte A, Paraskeva E, et al. Validated analysis of HIF-1a expression in cancer cells using a controlled and comparative immunoassay. Oncol Rep. 2010;24:161–9.PubMedCrossRef Ioannou M, Mylonis I, Kouvaras E, Papamichali R, Daponte A, Paraskeva E, et al. Validated analysis of HIF-1a expression in cancer cells using a controlled and comparative immunoassay. Oncol Rep. 2010;24:161–9.PubMedCrossRef
8.
go back to reference Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor-1 DNA binding activity: implications for models of hypoxia signal transduction. Blood. 1993;82:3610.PubMed Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor-1 DNA binding activity: implications for models of hypoxia signal transduction. Blood. 1993;82:3610.PubMed
9.
go back to reference Triantafyllou A, Liakos P, Tsakalof A, Georgatsou E, Simos G, Bonanou S. Cobalt induces hypoxia-inducible factor-1α (HIF-1α) in HeLa cells by an iron-independent, but ROS-, PI-3K- and MAPK-dependent mechanism. Free Radic Res. 2006;40:847.PubMedCrossRef Triantafyllou A, Liakos P, Tsakalof A, Georgatsou E, Simos G, Bonanou S. Cobalt induces hypoxia-inducible factor-1α (HIF-1α) in HeLa cells by an iron-independent, but ROS-, PI-3K- and MAPK-dependent mechanism. Free Radic Res. 2006;40:847.PubMedCrossRef
10.
go back to reference Rosenberger C, Solovan C, Rosenberger AD, Jinping L, Treudler R, Frei U, et al. Upregulation of hypoxia-inducible factors in normal and psoriatic skin. J Investig Dermatol. 2007;127:2445–52.PubMedCrossRef Rosenberger C, Solovan C, Rosenberger AD, Jinping L, Treudler R, Frei U, et al. Upregulation of hypoxia-inducible factors in normal and psoriatic skin. J Investig Dermatol. 2007;127:2445–52.PubMedCrossRef
11.
go back to reference Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6:578–87.PubMedCrossRef Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6:578–87.PubMedCrossRef
12.
go back to reference Kajihara I, Jinnin M, Honda N, Makino K, Makino T, Masuguchi S, et al. Scleroderma dermal fibroblasts overexpress vascular endothelial growth factor due to autocrine transforming growth factor β signaling. Mod Rheumatol;2012 (Epub ahead of print). Kajihara I, Jinnin M, Honda N, Makino K, Makino T, Masuguchi S, et al. Scleroderma dermal fibroblasts overexpress vascular endothelial growth factor due to autocrine transforming growth factor β signaling. Mod Rheumatol;2012 (Epub ahead of print).
Metadata
Title
Upregulation of VEGF expression is associated with accumulation of HIF-1α in the skin of naïve scleroderma patients
Authors
Maria Ioannou
Athina Pyrpasopoulou
Georgios Simos
Efrosyni Paraskeva
Christina Nikolaidou
Ioannis Venizelos
Georgios Koukoulis
Spyros Aslanidis
Stella Douma
Publication date
01-11-2013
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 6/2013
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-012-0787-6

Other articles of this Issue 6/2013

Modern Rheumatology 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine